{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:45:42Z","timestamp":1787028342102,"version":"build-2736575974"},"reference-count":83,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Meningococcal disease is caused by Neisseria meningitidis; 13 serogroups have been identified and differentiated from each other through their capsular polysaccharide. Serotypes A, B, C, W, X, and Y are responsible for nearly all infections worldwide. The most common clinical manifestations are meningitis and invasive meningococcal disease, both characterized by high mortality and long-term sequelae. The infection rate is higher in children younger than 1 year and in adolescents, who are frequently asymptomatic carriers. Vaccination is the most effective method of preventing infection and transmission. Currently, both monovalent meningococcal vaccines (against A, B, and C serotypes) and quadrivalent meningococcal vaccines (against serogroups ACYW) are available and recommended according to local epidemiology. The purpose of this article is to describe the meningococcal vaccines and to identify instruments that are useful for reducing transmission and implementing the vaccination coverage. This aim could be reached by switching from the monovalent to the quadrivalent vaccine in the first year of life, increasing vaccine promotion against ACYW serotypes among adolescents, and extending the free offer of the anti-meningococcal B vaccine to teens, co-administering it with others proposed in the same age group. Greater awareness of the severity of the disease and increased health education through web and social networks could represent the best strategies for promoting adhesion and active participation in the vaccination campaign. Finally, the development of a licensed universal meningococcal vaccine should be another important objective.<\/jats:p>","DOI":"10.3390\/ijerph19074035","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T21:44:52Z","timestamp":1648590292000},"page":"4035","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Meningococcal Disease in Pediatric Age: A Focus on Epidemiology and Prevention"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4935-8436","authenticated-orcid":false,"given":"Giada Maria","family":"Di Pietro","sequence":"first","affiliation":[{"name":"Pediatric Highly Intensive Care Unit, IRCCS Ca\u2019 Granda Foundation, Policlinico Hospital, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Biffi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo Luca","family":"Castellazzi","sequence":"additional","affiliation":[{"name":"Pediatric Emergency Department IRCCS Ca\u2019 Granda Foundation, Policlinico Hospital, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Tagliabue","sequence":"additional","affiliation":[{"name":"Pediatric Highly Intensive Care Unit, IRCCS Ca\u2019 Granda Foundation, Policlinico Hospital, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Pinzani","sequence":"additional","affiliation":[{"name":"Pediatric Highly Intensive Care Unit, IRCCS Ca\u2019 Granda Foundation, Policlinico Hospital, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Bosis","sequence":"additional","affiliation":[{"name":"Pediatric Highly Intensive Care Unit, IRCCS Ca\u2019 Granda Foundation, Policlinico Hospital, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-3920","authenticated-orcid":false,"given":"Paola Giovanna","family":"Marchisio","sequence":"additional","affiliation":[{"name":"Pediatric Highly Intensive Care Unit, IRCCS Ca\u2019 Granda Foundation, Policlinico Hospital, 20122 Milan, Italy"},{"name":"Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1542\/pir.2016-0131","article-title":"Meningococcal Disease","volume":"38","author":"Vaz","year":"2017","journal-title":"Pediatr. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","article-title":"Clinical recognition of meningococcal disease in children and adolescents","volume":"367","author":"Thompson","year":"2006","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yapd.2020.03.007","article-title":"Meningococcal Infections in Children and Adolescents: Update and Prevention","volume":"67","author":"Brady","year":"2020","journal-title":"Adv. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.jadohealth.2016.04.013","article-title":"Treatment of Meningococcal Disease","volume":"59","author":"Nadel","year":"2016","journal-title":"J. Adolesc. Health"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Pizza, M., Bekkat-Berkani, R., and Rappuoli, R. (2020). Vaccines against Meningococcal Diseases. Microorganisms, 8.","DOI":"10.3390\/microorganisms8101521"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0255-0857(21)02464-6","article-title":"Meningococcal disease: History, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention","volume":"24","author":"Manchanda","year":"2006","journal-title":"Indian J. Med. Micro-Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1542\/peds.2008-0581","article-title":"Outcomes of meningococcal disease in adolescence: Prospective, matched- cohort study","volume":"123","author":"Borg","year":"2009","journal-title":"Pediatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"R124","DOI":"10.1186\/cc9087","article-title":"Surviving meningococcal septic shock in childhood: Long-term overall outcome and the effect on health-related quality of life","volume":"14","author":"Buysse","year":"2010","journal-title":"Crit. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.vaccine.2014.05.069","article-title":"The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children","volume":"32","author":"Wang","year":"2014","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1093\/cid\/civ028","article-title":"Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: A prospective cohort study","volume":"60","author":"Sadarangani","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: Sequelae and quality of life impact on patients and their car-egivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_12","unstructured":"Centers for Disease Control and Prevention (2021, December 28). Meningococcal Disease Surveillance, Available online: https:\/\/www.cdc.gov\/meningococcal\/surveillance\/index.html."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis","volume":"362","author":"Tan","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"010409","DOI":"10.7189\/jogh.09.010409","article-title":"Meningococcal Surveillance Group. Meningococcal serogroups and surveillance: A systematic review and survey","volume":"9","author":"Peterson","year":"2019","journal-title":"J. Glob. Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/QCO.0000000000000580","article-title":"Meningitis vaccines in children: What have we achieved and where next?","volume":"32","author":"McAlpine","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_16","first-page":"116","article-title":"Clinical presentation of meningococcal disease in childhood","volume":"53","author":"Sabatini","year":"2012","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"ECDC network members for invasive meningococcal disease. The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"key":"ref_18","unstructured":"European Centre for Disease Prevention and Control (ECDC) (2021, December 28). Invasive Meningococcal Disease. Annual Epidemiological Report for 2017. Available online: https:\/\/www.ecdc.europa.eu\/en\/meningococcal-disease\/surveillance-and-disease-data\/aer."},{"key":"ref_19","first-page":"E152","article-title":"Invasive meningococcal disease in Italy: From analysis of national data to an evidence-based vaccination strategy","volume":"61","author":"Igidbashian","year":"2020","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2017.04.078","article-title":"Polysaccharide conjugate vaccine protein carriers as a \u201cneglected valency\u201d\u2014Potential and limitations","volume":"35","author":"Berti","year":"2017","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1080\/21645515.2020.1733867","article-title":"Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study","volume":"16","author":"Hedrick","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1099\/0022-1317-51-9-717","article-title":"Impact of meningococcal C conjugate vaccine in the UK","volume":"51","author":"Balmer","year":"2002","journal-title":"J. Med. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: The experience in England and Wales","volume":"27","author":"Campbell","year":"2009","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","article-title":"The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination","volume":"81","author":"Parikh","year":"2020","journal-title":"J. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Tin Tin Htar, M., Jackson, S., Balmer, P., Serra, L.C., Vyse, A., Slack, M., Riera-Montes, M., Swerdlow, D.L., and Findlow, J. (2020). Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs. BMC Public Health, 20.","DOI":"10.1186\/s12889-020-09946-1"},{"key":"ref_27","unstructured":"(2022, January 14). Istituto Superiore di Sanit\u00e0, Available online: https:\/\/www.trovanorme.salute.gov.it\/norme\/renderNormsanPdf?anno=2017&codLeg=58583&parte=1%20&serie=null."},{"key":"ref_28","unstructured":"(2022, January 14). World Health Organization, Meningococcal Disease, Vaccine and Vaccination. Available online: http:\/\/www.emro.who.int\/health-topics\/meningococcal-disease\/vaccine-vaccination.html."},{"key":"ref_29","unstructured":"European Centre for Disease Prevention and Control (2022, January 15). Surveillance of Invasive Bacterial Diseases in Europe. Available online: http:\/\/www.ecdc.europa.eu\/en\/publications\/Publications\/101011_SUR_Surveillance_of_invasive_bacterial_diseases_in_Europe_2007.pdf."},{"key":"ref_30","unstructured":"(2022, January 15). Istituto Superiore di Sanit\u00e0. Available online: https:\/\/www.iss.it\/documents\/20126\/0\/Rapporto+MaBI+2020.pdf\/a2d63000-2b68-56d9-bdf2-b471bd77417d?t=1636559360665."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity","volume":"197","author":"Maiden","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.vaccine.2014.03.010","article-title":"Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification","volume":"32","author":"Herruzo","year":"2014","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/21645515.2019.1688032","article-title":"Co-administration of vaccines: A focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines","volume":"16","author":"Bonanni","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_34","unstructured":"(2022, January 17). Agenzia Italiana del Farmaco, Available online: https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_007127_035436_RCP.pdf&retry=0&sys=m0b1l3."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(17)30301-8","article-title":"Impact of MenAfriVac in nine countries of the African meningitis belt, 2010\u20132015: An analysis of surveillance data","volume":"17","author":"Trotter","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"ref_36","unstructured":"(2022, January 20). Menactra, Available online: https:\/\/www.fda.gov\/media\/75619\/download."},{"key":"ref_37","unstructured":"(2022, January 20). Menveo, Available online: https:\/\/www.fda.gov\/media\/78514\/download."},{"key":"ref_38","unstructured":"(2022, January 20). Menquadfi, Available online: https:\/\/www.fda.gov\/media\/137306\/download."},{"key":"ref_39","unstructured":"(2022, January 20). Nimenrix. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nimenrix-epar-product-information_en.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/INF.0000000000000930","article-title":"Safety and Immunogenicity of a Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration","volume":"35","author":"Gasparini","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current Epidemiology and Trends in Meningococcal Disease-United States, 1996\u20132015","volume":"66","author":"MacNeil","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jamapediatrics.2020.1990","article-title":"Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States","volume":"174","author":"Mbaeyi","year":"2020","journal-title":"JAMA Pediatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"ref_44","unstructured":"Ministero della Salute (2022, January 29). Vaccinazioni Dell\u2019et\u00e0 Pediatrica e Dell\u2019adolescenza\u2014Coperture Vaccinali, Available online: https:\/\/www.salute.gov.it\/portale\/documentazione\/p6_2_8_3_1.jsp?lingua=italiano&id=20."},{"key":"ref_45","first-page":"149.e50","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-na\u00efve and meningococcal C conjugate vaccine-primed toddlers: A phase III randomised study","volume":"5","author":"Vesikari","year":"2021","journal-title":"Epidemiol. Infect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1179\/2047773214Y.0000000162","article-title":"Bexsero\u00ae chronicle","volume":"108","author":"Vernikos","year":"2014","journal-title":"Pathog. Glob. Health."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/femspd\/ftx033","article-title":"Novel approaches to Neisseria meningitidis vaccine","volume":"75","author":"Christodoulides","year":"2017","journal-title":"Pathog. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"402381","DOI":"10.1155\/2015\/402381","article-title":"Meningococcal B Vaccination (4CMenB) in Infants and Toddlers","volume":"2015","author":"Esposito","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_49","unstructured":"Gruppo di Lavoro del CNESP (2022, January 04). Istituto Superiore di Sanit\u00e0. Dati e Evidenze Disponibili per L\u2019introduzione della Vaccinazione Antimeningococco B Nei Nuovi Nati e Negli Adolescenti. Available online: https:\/\/www.epicentro.iss.it\/vaccini\/pdf\/Istruttoria%20MENINGOCOCCO%20B.pdfww.epicentro.iss.it."},{"key":"ref_50","unstructured":"AIFA (2022, January 04). Bexsero-B. Foglio Illustrativo, Available online: https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_007127_042687_FI.pdf&sys=m0b1l3."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Boccalini, S., Zanella, B., Landa, P., Amicizia, P., Bechini, A., Innocenti, M., Iovine, M., Lecini, E., Marchini, F., and Paolini, D. (2020). Why the anti\u2014Meningoccocal B vaccination during adolescent should be implemented in Italy: An overview of available evidence. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111681"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine\u2014Advisory Committee on Immunization Practices, 2016","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.vaccine.2013.09.055","article-title":"Distribution of invasive meningococcal B disease in Italian pediatric population: Implications for vaccination timing","volume":"32","author":"Azzari","year":"2014","journal-title":"Vaccine"},{"key":"ref_55","unstructured":"European Surveillance System (2022, January 04). Invasive Meningococcal Disease. Annual Epidemiological Report for 2017. Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER_for_2017-invasive-meningococcal-disease.pdf."},{"key":"ref_56","first-page":"E125","article-title":"Meningococcal serogroup B vaccine in Italy: State-of-art, organizational aspects and perspectives","volume":"56","author":"Signorelli","year":"2015","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jadohealth.2016.03.040","article-title":"Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations","volume":"59","author":"Baker","year":"2016","journal-title":"J. Adolesc. Health"},{"key":"ref_58","unstructured":"Government of Canada (2022, January 10). Meningococcal Vaccine: Canadian Immunization Guide Part 4\u2014Active Vaccines. Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-13-meningococcal-vaccine.html."},{"key":"ref_59","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2022, January 08). Riassunto Caratteristiche del Prodotto. Trumenba\u00ae, Available online: https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfwnloadServlet?pdfFileName=footer_004849_045429_RCP.pdf&retry=0&sys=m0b1l3."},{"key":"ref_60","unstructured":"European Centre for Disease Prevention and Control (2022, January 08). Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU\/EEA. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/expert-opinion-introduction-meningococcal-b-4cmenb-vaccine-eueea#:~:text=The%204CMenB%20vaccine%20has%20been,on%20a%202%2B1%20schedule."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.vaccine.2017.05.023","article-title":"Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial","volume":"35","author":"Safadi","year":"2017","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/infdis\/jix446","article-title":"Meningococcal Carriage Following a University Serogroup B Meningococcal Disease Outbreak and Vaccination Campaign with MenB-4C and MenB-FHbp\u2014Oregon, 2015\u20132016","volume":"216","author":"McNamara","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/21645515.2018.1450121","article-title":"Neisseria Meningitidis Serogroup B Carriage by Adolescents and Young Adults Living in Milan, Italy: Prevalence of strains potentially covered by the presently available meningococcal B vaccines","volume":"14","author":"Terranova","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1128\/JCM.03584-13","article-title":"Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years","volume":"52","author":"Gasparini","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Miglietta, A., Innocenti, F., Pezzotti, P., Riccobono, E., Moriondo, M., Pecile, P., Nieddu, F., Rossolini, G.M., Azzari, C., and Meningococcal Carriage Study Group (2019). Carriage rates and risk factors during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C ST-11 (cc11) in Tuscany, Italy: A cross-sectional study. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-018-3598-3"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/21645515.2018.1528831","article-title":"Meningococcal disease in adolescents and young adults: A review of the rationale for prevention through vaccination","volume":"15","author":"Burman","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_68","first-page":"E1","article-title":"Health Technology Assessment (HTA) del vaccino anti-meningococco B (Trumenba\u00ae) per gli adolescenti in Italia","volume":"60","author":"Boccalini","year":"2019","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMe1916440","article-title":"Good News and Bad News\u20144CMenB Vaccine for Group B Neisseria meningitidis","volume":"382","author":"Harrison","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.micpath.2013.02.003","article-title":"Neisseria meningitidis serogroup B vaccine development","volume":"57","author":"Caesar","year":"2013","journal-title":"Microb. Pathog."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.vaccine.2013.09.034","article-title":"Evaluation of serogroup C and ACWY meningococcal vaccine programs: Projected impact on disease burden according to a stochastic two-strain dynamic model","volume":"33","author":"Vickers","year":"2015","journal-title":"Vaccine"},{"key":"ref_72","unstructured":"World Health Organization (WHO) (2022, January 15). Vaccine Introduction Guidelines. Adding a Vaccine to the National Immunization Programme. Decision and Implementation., Available online: http:\/\/whqlibdoc.who.int\/hq\/2005\/WHO_IVB_05.18.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/21645515.2018.1436918","article-title":"Meningococcal disease and vaccination: Knowledge and acceptability among adolescents in Italy","volume":"14","author":"Pelullo","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1080\/21645515.2017.1421877","article-title":"Vaccinations among Italian adolescents: Knowledge, attitude and behavior","volume":"14","author":"Pelullo","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2711709","DOI":"10.17061\/phrp2711709","article-title":"Communicating about risk: Strategies for situations where public concern is high, but the risk is low","volume":"27","author":"Hooker","year":"2017","journal-title":"Public Health Res. Pract."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1017\/dmp.2014.36","article-title":"Risk communication and crisis communication in infectious disease outbreaks in Germany: What is being done, and what needs to be done","volume":"8","author":"Dickmann","year":"2014","journal-title":"Dis. Med. Public Health Prep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1746-1561.2009.00482.x","article-title":"Strategies for implementing school-located influenza vaccination of children: A systematic literature review","volume":"80","author":"Cawley","year":"2010","journal-title":"J. Sch. Health"},{"key":"ref_78","first-page":"E225","article-title":"Universal proposal strategies of anti-HPV vaccination for adolescents: Comparative analysis between school-based and clinic immunization programs","volume":"58","author":"Desiante","year":"2017","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.inf.0000166161.12087.94","article-title":"Challenges to vaccinating adolescents: Vaccine implementation issues","volume":"24","author":"Humiston","year":"2005","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1542\/peds.2007-1115F","article-title":"The he role of schools in strengthening delivery of new adolescent vaccinations","volume":"121","author":"Lindley","year":"2008","journal-title":"Pediatrics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1080\/21645515.2019.1581542","article-title":"Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: A review of available evidence","volume":"15","author":"Alderfer","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1056\/NEJMoa2013615","article-title":"Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers","volume":"384","author":"Tapia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e0055321","DOI":"10.1128\/mSphere.00553-21","article-title":"Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: A Phase 2 Randomized Study of Adolescents and Young Adults","volume":"6","author":"Beran","year":"2021","journal-title":"Msphere"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/7\/4035\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:45:30Z","timestamp":1760136330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/7\/4035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":83,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijerph19074035"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19074035","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]}}}